Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.50 |
| ▸ | CTSK | P43235 | 8/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9679279 | 0.90 | CTSS (0.47) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29147405 | 0.86 | CTSS (0.67) | CTSSCTSKCA2 | |
| SCHEMBL26206757 | 0.83 | CTSK (0.48) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19560807 | 0.83 | CTSK (0.48) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15369701 | 0.83 | CTSS (0.63) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL46641 | 0.81 | PPARA (0.57) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2313666 | 0.81 | PPARA (0.57) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1618767 | 0.81 | PPARA (0.57) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25293909 | 0.81 | CTSK (0.65) | CTSSCTSKCTSLCTSBCA2 | |
| SCHEMBL13955236 | 0.81 | CTSK (0.46) | CTSSCTSKCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133141-B2 | Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140155440-A1 | CYSTEINE AND CYSTINE BIOISOSTERES TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155440-A1 | CYSTEINE AND CYSTINE BIOISOSTERES TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, CBS, SLC7A11 | CTSS 210/4885CTSK 669/4885CYP1A2 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.